Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study
B Flower, L Mccabe, MA Ansari, C Le Ngoc, TV Thi… - Elife, 2023 - elifesciences.org
Background: World Health Organization has called for research into predictive factors for
selecting persons who could be successfully treated with shorter durations of direct-acting …
selecting persons who could be successfully treated with shorter durations of direct-acting …
Four Weeks Treatment with Glecaprevir/Pibrentasvir+ Ribavirin—A Randomized Controlled Clinical Trial
LW Madsen, PB Christensen, JF Hansen, BT Røge… - Viruses, 2022 - mdpi.com
Enhancing treatment uptake for hepatitis C to achieve the elimination goals set by the World
Health Organization could be achieved by reducing the treatment duration. The aim of this …
Health Organization could be achieved by reducing the treatment duration. The aim of this …
Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus
A Sy, L McCabe, E Hudson, AM Ansari, V Pedergnana… - Plos one, 2023 - journals.plos.org
Background The CC genotype of the IFNL4 gene is known to be associated with increased
Hepatitis C (HCV) cure rates with interferon-based therapy and may contribute to cure with …
Hepatitis C (HCV) cure rates with interferon-based therapy and may contribute to cure with …
Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis C
LW Madsen, PB Christensen, A Øvrehus… - Frontiers in Cellular …, 2022 - frontiersin.org
Reducing the treatment duration for chronic hepatitis C could be an important tool in the
effort to reach the elimination goals set by the World Health Organization. The current …
effort to reach the elimination goals set by the World Health Organization. The current …
Rise in alanine aminotransferase after HCV treatment is a highly sensitive screen for treatment failure
B Flower, PNT Ngoc, L McCabe, C Le Ngoc… - Clinical Liver …, 2023 - journals.lww.com
Nucleic acid testing to confirm sustained virological response (SVR) after HCV therapy is
technical, often expensive, and frequently unavailable where disease prevalence is highest …
technical, often expensive, and frequently unavailable where disease prevalence is highest …
Modeling-Based Response-Guided Hepatitis C Treatment During Pregnancy and Postpartum
T Kushner, CT Nyabanga, SJ Cotler… - Open Forum …, 2023 - academic.oup.com
Treating hepatitis C virus (HCV) in pregnancy would address HCV during prenatal care and
potentially reduce the risk of vertical transmission. Response-guided therapy could provide …
potentially reduce the risk of vertical transmission. Response-guided therapy could provide …
Barriers to hepatitis C virus elimination: treatment discontinuation, treatment failure, and reinfection
J Carson - 2023 - unsworks.unsw.edu.au
Background: Direct-acting antiviral (DAA) treatment is being scaled up to eliminate hepatitis
C virus (HCV) as a major public health threat. Aims: The aim of this research was to assess …
C virus (HCV) as a major public health threat. Aims: The aim of this research was to assess …
Clinical, immunological and virological aspects of short duration treatment for chronic hepatitis C
LW Madsen - 2022 - portal.findresearcher.sdu.dk
Background The introduction of direct-acting antivirals (DAA) has led to a paradigm shift in
the treatment for chronichepatitis C with cure rates above 95% after 8-12 weeks treatment …
the treatment for chronichepatitis C with cure rates above 95% after 8-12 weeks treatment …
[PDF][PDF] Interventions for Impact: Studies on Improving Care for People at Risk of Hepatitis C Virus Infection
C Byrne - 2022 - discovery.dundee.ac.uk
The World Health Organization (WHO) estimates that approximately 37 million people are
living with HIV (PLHIV) globally; of these, 2.9 million are co-infected with hepatitis C virus …
living with HIV (PLHIV) globally; of these, 2.9 million are co-infected with hepatitis C virus …